类风湿关节炎达标治疗:一项质量改进试验
该非随机中断时间序列试验纳入554例类风湿关节炎患者共709次就诊,评估学习协作干预对风湿科医生记录达标治疗实施情况的影响。干预组达标治疗实施评分较对照组提高12.4%(44.6% vs 32.2%,P<0.0001),但高RAPID3评分患者中干预组调整药物的可能性反而降低54%(OR 0.46,95%CI 0.27-0.79,P=0.005)。
要点
- 学习协作干预可适度但显著提高达标治疗实施评分(提高12.4%)。
- 干预组在疾病活动度评分记录、用于决策、治疗目标及共享决策方面均优于对照组。
- 高RAPID3评分患者中干预组调整药物的可能性反而降低54%。
核心结论
- 学习协作干预对风湿科医生记录类风湿关节炎达标治疗有适度但显著的影响。
研究设计与样本
- 非随机中断时间序列试验,纳入554例类风湿关节炎患者共709次就诊,9名风湿科医生及患者分配至学习协作干预组,13名分配至对照组。
主要发现
- 干预组达标治疗实施评分平均44.6%±1.63%,对照组32.2%±1.50%,干预组高12.4%(P<0.0001)。
- 干预组与对照组比较:疾病活动度评分存在率77.2% vs 68.0%(P=0.02);疾病活动度评分用于药物调整决策45.2% vs 30.0%(P<0.01);治疗目标9.0% vs 0.4%(P<0.01);共享决策46.9% vs 30.0%(P<0.01)。
- 高RAPID3评分就诊的二次分析中,干预组调整药物的可能性较对照组低54%(OR 0.46,95%CI 0.27-0.79,P=0.005)。
关键数值与推荐
- 达标治疗实施评分包括疾病活动度评分、疾病活动度评分用于药物调整决策、存在治疗目标及共享决策的记录。
临床怎么用
- 学习协作干预可改善达标治疗相关记录,但需关注高疾病活动度患者中药物调整可能不足的问题。
局限性
- 研究为非随机设计,样本来自单一质量改进项目,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Using a quality improvement approach, our objective was to integrate a treat-to-target approach for rheumatoid arthritis (RA) through routine electronic collection of patient-reported disease activity scores and a multidisciplinary learning collaborative for rheumatologists. METHODS: RA patients completed a patient-reported outcome measure, the Routine Assessment of Patient Index Data 3 (RAPID3), at check-in. Nine rheumatologists and their patients were allocated to a learning collaborative intervention group focused on a treat-to-target approach and 13 were allocated to a control group. The primary outcome was documentation of a treat-to-target implementation score: disease activity score, disease activity score used in the medication change decision, the presence of a treatment target, and an indication of shared decision-making. A primary analysis of patient visits with medication changes was conducted using an interrupted time-series analysis. RESULTS: We studied 554 individual rheumatology patients with 709 patient visits. Treat-to-target implementation scores among intervention rheumatologists (mean ± SD 44.6% ± 1.63%) were 12.4% higher than in the control group (mean ± SD 32.2% ± 1.50%; P < 0.0001). We observed differences in treat-to-target implementation score components, comparing intervention group to control group rheumatologists: disease activity score present, 77.2% versus 68.0% (P = 0.02); disease activity score used in the medication change decision, 45.2% versus 30.0% (P < 0.01); treatment target, 9.0% versus 0.4% (P < 0.01); and shared decision-making, 46.9% versus 30.0% (P < 0.01). Secondary analysis of patient visits with high RAPID3 scores found that medication changes were 54% less likely in the intervention versus control group (odds ratio 0.46 [95% confidence interval 0.27-0.79], P = 0.005). CONCLUSION: This nonrandomized, interrupted time-series trial demonstrated a modest but significant impact of a learning collaborative intervention on rheumatologist documentation of a treat-to-target approach in RA.
引用
- Desai SP, Leatherwood C, Forman M, et al. Treat-to-Target Approach in Rheumatoid Arthritis: A Quality Improvement Trial. Arthritis Care Res (Hoboken). 2021. PMID: 31758663. doi:10.1002/acr.24114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。